1Mottet C, Golshayan D. CD4 + CD25 + Foxp3 + regulatory T cells: from basic research to potential therapeutic use[J]. Swiss Med Wkly, 2007,137 (45 46 ) :625 -634.
2Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success [ J ]. Nat Rev Immunol, 2006,6(5 ) :383-393.
3Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting[J].Immunity, 2004,21 (2) : 137-148.
4Marincola FM, Jaffee EM, Hicklin D J, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance [ J ]. Adv Immunol, 2000,74 ( 1 ) : 181-273.
7Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-toletizing host tumor-specific CD8 T cells[J].J lmmunol, 2003,170(10) :4905-4913.
8Casares N, Pequignot MO, Tesnierc A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death[J]. J Exp Med, 2005,202 ( 12 ) : 1691-1701.
9Lake RA, van der Most RG. A better way for a caneer eell to die [ J]. N Engl J Med, 2006,354 (23) :2503-2504.
10Gasser S, Raulet DH. The DNA damage response arouses the immune system [ J ]. Cancer Res, 2006,66 ( 8 ) :3959-3962.
